News FDA clears first drug for MCT8 deficiency Sweden's Egetis has won approval in the US for the first-ever treatment for people living with the ultra-rare genetic disease MCT8 deficiency.
News AZ takes stake in Summit Therapeutics in $2bn deal AstraZeneca has taken a roughly 10% stake in Summit and signed a deal to test CLDN18.2-targeting sone-ve with PD-1xVEGF bispecific ivonescimab.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.